NO305172B1 - (E)-3-[2-n-butyl-1-{ (4-karboksyfenyl)metyl}-1H-imidazol-5-yl]-2-(2-tienyl)metyl-2-propensyremetansulfonat, farmas°ytisk preparat pÕ basis av og anvendelse derav - Google Patents

(E)-3-[2-n-butyl-1-{ (4-karboksyfenyl)metyl}-1H-imidazol-5-yl]-2-(2-tienyl)metyl-2-propensyremetansulfonat, farmas°ytisk preparat pÕ basis av og anvendelse derav

Info

Publication number
NO305172B1
NO305172B1 NO940476A NO940476A NO305172B1 NO 305172 B1 NO305172 B1 NO 305172B1 NO 940476 A NO940476 A NO 940476A NO 940476 A NO940476 A NO 940476A NO 305172 B1 NO305172 B1 NO 305172B1
Authority
NO
Norway
Prior art keywords
methyl
carboxyphenyl
imidazol
thienyl
butyl
Prior art date
Application number
NO940476A
Other languages
English (en)
Norwegian (no)
Other versions
NO940476L (no
NO940476D0 (no
Inventor
Richard Mccullock Keenan
Joseph Weinstock
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO940476D0 publication Critical patent/NO940476D0/no
Publication of NO940476L publication Critical patent/NO940476L/no
Publication of NO305172B1 publication Critical patent/NO305172B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO940476A 1991-08-14 1994-02-11 (E)-3-[2-n-butyl-1-{ (4-karboksyfenyl)metyl}-1H-imidazol-5-yl]-2-(2-tienyl)metyl-2-propensyremetansulfonat, farmas°ytisk preparat pÕ basis av og anvendelse derav NO305172B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/746,262 US5185351A (en) 1989-06-14 1991-08-14 Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
PCT/US1992/006734 WO1993003722A1 (en) 1991-08-14 1992-08-12 Imidazolyl-alkenoic acids

Publications (3)

Publication Number Publication Date
NO940476D0 NO940476D0 (no) 1994-02-11
NO940476L NO940476L (no) 1994-04-11
NO305172B1 true NO305172B1 (no) 1999-04-12

Family

ID=25000103

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940476A NO305172B1 (no) 1991-08-14 1994-02-11 (E)-3-[2-n-butyl-1-{ (4-karboksyfenyl)metyl}-1H-imidazol-5-yl]-2-(2-tienyl)metyl-2-propensyremetansulfonat, farmas°ytisk preparat pÕ basis av og anvendelse derav

Country Status (33)

Country Link
US (1) US5185351A (ro)
EP (1) EP0641203B1 (ro)
JP (1) JPH07500579A (ro)
CN (1) CN1036396C (ro)
AP (3) AP525A (ro)
AT (1) ATE226073T1 (ro)
AU (1) AU667824B2 (ro)
BG (1) BG61593B1 (ro)
BR (1) BR9206443A (ro)
CA (1) CA2115170C (ro)
CZ (1) CZ281635B6 (ro)
DE (1) DE69232817T2 (ro)
DK (1) DK0641203T3 (ro)
ES (1) ES2185617T3 (ro)
FI (1) FI114796B (ro)
HK (1) HK1012246A1 (ro)
HU (1) HU225048B1 (ro)
IL (1) IL102813A (ro)
MA (1) MA22626A1 (ro)
MX (1) MX9204737A (ro)
MY (1) MY110205A (ro)
NO (1) NO305172B1 (ro)
NZ (1) NZ243966A (ro)
OA (1) OA09884A (ro)
PL (1) PL177234B1 (ro)
PT (1) PT100779B (ro)
RO (1) RO113643B1 (ro)
RU (1) RU2124513C1 (ro)
SK (1) SK281252B6 (ro)
TW (1) TW234690B (ro)
UA (1) UA40587C2 (ro)
WO (1) WO1993003722A1 (ro)
ZA (1) ZA926133B (ro)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
US5418250A (en) * 1989-06-14 1995-05-23 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
US6028091A (en) * 1990-12-14 2000-02-22 Smithkline Beecham Plc Medicament
GB9027200D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
US6025380A (en) * 1990-12-14 2000-02-15 Smithkline Beecham Plc Medicament
US6034114A (en) * 1990-12-14 2000-03-07 Smithkline Beecham Plc Medicament
AU9137791A (en) * 1990-12-14 1992-07-08 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
US5447949A (en) * 1991-05-15 1995-09-05 Smithkline Beecham Corporation N-(heteroaryl) imidazolyl-alkenoic acids having angiotension II receptor antagonist activity
US20030166700A1 (en) * 1991-12-12 2003-09-04 Smithkline Beecham P.L.C. Medicament
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
DE4206043A1 (de) * 1992-02-27 1993-09-02 Bayer Ag Sulfonylbenzyl-substituierte imidazole
US5401851A (en) * 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists
US5824696A (en) * 1993-09-01 1998-10-20 Smithkline Beecham Corporation Medicaments
US5395847A (en) * 1993-12-02 1995-03-07 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
EP0850225B1 (en) * 1994-05-20 2003-08-13 Smithkline Beecham Corporation Intermediate for preparing a pharmaceutically active compound
AU702661B2 (en) * 1994-06-29 1999-02-25 Smithkline Beecham Corporation Vitronectin receptor antagonists
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US6613789B2 (en) 1994-07-28 2003-09-02 G. D. Searle & Co. Heterocyclo-substituted imidazoles for the treatment of inflammation
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
US6420412B2 (en) 1996-03-29 2002-07-16 Smithkline Beecham Corporation Eprosartan dihydate and a process for its production and formulation
ES2198564T3 (es) * 1996-03-29 2004-02-01 Smithkline Beecham Corporation Dihidrato de eprosartan y un procedimiento para su produccion y formulacion.
AR011125A1 (es) * 1997-02-14 2000-08-02 Smithkline Beecham Corp Procedimiento para preparar eprosartano
AR011126A1 (es) * 1997-02-14 2000-08-02 Smithkline Beecham Corp Procedimiento para preparar eprosartano y compuestos intermediarios.
US20030045561A1 (en) * 2001-02-06 2003-03-06 Smithkline Beecham Corporation Method of treating isolated systolic hypertension
ZA984421B (en) * 1997-05-27 1998-11-27 Smithkline Beecham Corp Method of treating isolated systolic hypertension
CA2294515C (en) 1997-06-27 2007-08-28 Smithkline Beecham Corporation Eprosartan monohydrate
US6630498B2 (en) 1997-08-06 2003-10-07 Smithkline Beecham Corporation Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation
IL134378A (en) * 1997-08-06 2004-02-19 Smithkline Beecham Corp A complex that neutralizes the charge of aprosartan arginine, its preparation and pharmaceutical preparations containing it
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
KR100597922B1 (ko) * 1997-11-17 2006-07-10 스미스클라인 비참 코포레이션 고용량 약물 로딩 속효성 및 변형 방출형 경구 투여용제형 및 그의 제조 방법
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
US6517871B1 (en) * 1998-07-20 2003-02-11 Smithkline Beecham Corporation Bioenhanced formulations comprising eprosartan in oral solid dosage form
DK1100789T3 (da) 1998-07-24 2005-05-23 Bayer Cropscience Ag Substituerede benzoylcyclohexandioner
DE19920791A1 (de) 1999-05-06 2000-11-09 Bayer Ag Substituierte Benzoylisoxazole
DE19921424A1 (de) 1999-05-08 2000-11-09 Bayer Ag Substituierte Benzoylketone
DE19946853A1 (de) 1999-09-30 2001-04-05 Bayer Ag Substituierte Arylketone
DE10004084A1 (de) * 2000-01-31 2001-08-02 Bayer Ag Substituierte Imid-Derivate
DE10221121A1 (de) * 2002-05-13 2003-12-04 Bayer Cropscience Ag N'-Cyano-N-methyl-imidamid-Derivate
ATE502635T1 (de) 2002-08-19 2011-04-15 Pfizer Kombinationstherapie gegen hyperproliferative erkrankungen
NZ543741A (en) * 2003-05-30 2009-10-30 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-Co inhibitors
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
ES2304624T3 (es) * 2003-10-10 2008-10-16 Solvay Pharmaceuticals Gmbh Composicion farmaceutica que comprende un agonista selectivo del receptor de imidazolina l1 y un bloqueador del receptor de angiotensina ii.
US20060099230A1 (en) * 2004-11-10 2006-05-11 Chin-Chih Chiang Novel formulations of eprosartan with enhanced bioavailability
KR20070084455A (ko) * 2004-11-23 2007-08-24 워너-램버트 캄파니 엘엘씨 지질혈증 치료용 ｈｍｇ ｃｏ-ａ 환원효소 억제제로서의7-(2ｈ-피라졸-3-일)-3,5-디히드록시-헵탄산 유도체
EP1752450A1 (en) 2005-08-01 2007-02-14 Merck Sante Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
JP2009514851A (ja) * 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US20090270474A1 (en) * 2005-12-06 2009-10-29 Keiichi Shibagaki Therapeutic Agent for Keratoconjunctival Disorder
AR059838A1 (es) * 2006-03-14 2008-04-30 Ranbaxy Lab Ltd Formulaciones para dosis estabilizantes de estatina
JP2009543773A (ja) * 2006-07-14 2009-12-10 ランバクシー ラボラトリーズ リミテッド ＨＭＧ−ＣｏＡレダクターゼ阻害剤の多形体及びその使用
US20080014263A1 (en) * 2006-07-17 2008-01-17 Glenmark Pharmaceuticals Limited Amorphous eprosartan mesylate and process for the preparation thereof
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
US20100137613A1 (en) * 2006-12-27 2010-06-03 Hetero Drugs Limited Process for eprosartan
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2181109A4 (en) * 2007-07-25 2011-08-03 Hetero Drugs Ltd CRYSTALLINE PARTICLES OF EPROSARTAN MESYLATE AND PROCESS FOR PREPARING PURE EPROSARTAN
EP2295431A3 (en) * 2007-07-25 2011-08-03 Hetero Drugs Limited Substantially pure eprosartan free base
MX2010004402A (es) * 2007-10-22 2010-10-15 Orchid Res Lab Ltd Inhibidores de histona deacetilasa.
WO2009084028A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd Improved process for manufacturing anhydrous (e)-3-[2-butyl-1- {(4-carboxyphenyl) methyl}-1h-imidazole-5-yl]-(thiophen-2- ylmethyl)prop-2-enoic acid methane sulfonate
CN101215284B (zh) * 2007-12-31 2010-10-13 浙江华海药业股份有限公司 一种改进的依普罗沙坦的制备方法
US20110054186A1 (en) * 2008-03-31 2011-03-03 Hetero Research Foundation Process for eprosartan intermediate
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CN101333216A (zh) * 2008-08-03 2008-12-31 浙江华海药业股份有限公司 一种新的依普罗沙坦甲磺酸盐成盐工艺
WO2010075347A2 (en) 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
WO2011004384A2 (en) 2009-06-05 2011-01-13 Glochem Industries Limited Process for the preparation of eprosartan
WO2011051975A1 (en) 2009-10-30 2011-05-05 Matrix Laboratories Ltd An improved process for the preparation of pure eprosartanand its pharmaceutical acceptable salts
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2846387C (en) 2011-08-26 2016-02-09 Wockhardt Limited Methods for treating cardiovascular disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
JP6422868B2 (ja) 2013-07-23 2018-11-14 第一三共株式会社 高血圧症の予防又は治療のための医薬
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CA3015964C (en) 2016-03-24 2021-08-03 Daiichi Sankyo Company, Limited Medicine for treating renal disease
AU2019287551A1 (en) 2018-06-14 2021-01-28 Astrazeneca Uk Limited Methods for treatment of hypertension with an angiotensin II receptor blocker pharmaceutical composition
JP7128969B2 (ja) 2019-01-18 2022-08-31 アストラゼネカ・アクチエボラーグ Ｐｃｓｋ９阻害剤及びその使用方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
JPS5671073A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
JPS58157768A (ja) * 1982-03-16 1983-09-19 Takeda Chem Ind Ltd ４−クロロ−２−フエニルイミダゾ−ル−５−酢酸誘導体
US4668794A (en) * 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
ATE250587T1 (de) * 1989-06-14 2003-10-15 Smithkline Beecham Corp Imidazoalkensäure
AU640417B2 (en) * 1989-10-25 1993-08-26 Smithkline Beecham Corporation Substituted 5-((tetrazolyl)alkenyl)imidazoles
GB9027197D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
AU9137791A (en) * 1990-12-14 1992-07-08 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
GB9027208D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
JP3398379B2 (ja) * 1990-12-14 2003-04-21 スミスクライン・ビーチャム・コーポレイション アンジオテンシンｉｉ受容体遮断組成物
GB9027198D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027209D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027201D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027199D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027210D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027211D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027212D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027200D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments

Also Published As

Publication number Publication date
CN1036396C (zh) 1997-11-12
EP0641203B1 (en) 2002-10-16
AP9200416A0 (en) 1992-10-31
FI114796B (fi) 2004-12-31
AP527A (en) 1996-09-06
BR9206443A (pt) 1994-09-27
TW234690B (ro) 1994-11-21
HK1012246A1 (en) 1999-07-30
CA2115170A1 (en) 1993-03-04
NZ243966A (en) 1996-08-27
MY110205A (en) 1998-02-28
AP526A (en) 1996-09-06
BG61593B1 (bg) 1998-01-30
AP9500742A0 (en) 1995-07-31
AU667824B2 (en) 1996-04-18
OA09884A (en) 1994-09-15
EP0641203A1 (en) 1995-03-08
DE69232817T2 (de) 2003-06-18
NO940476L (no) 1994-04-11
ES2185617T3 (es) 2003-05-01
HUT70157A (en) 1995-09-28
DE69232817D1 (de) 2002-11-21
WO1993003722A1 (en) 1993-03-04
ZA926133B (en) 1993-03-31
JPH07500579A (ja) 1995-01-19
FI940642A (fi) 1994-02-11
RU2124513C1 (ru) 1999-01-10
CN1070645A (zh) 1993-04-07
CA2115170C (en) 2004-05-25
US5185351A (en) 1993-02-09
AP9500741A0 (en) 1995-07-31
DK0641203T3 (da) 2003-02-17
CZ281635B6 (cs) 1996-11-13
HU9400413D0 (en) 1994-05-30
IL102813A0 (en) 1993-01-31
BG98454A (bg) 1995-02-28
HU225048B1 (en) 2006-05-29
UA40587C2 (uk) 2001-08-15
ATE226073T1 (de) 2002-11-15
CZ31194A3 (en) 1994-12-15
PL177234B1 (pl) 1999-10-29
SK281252B6 (sk) 2001-01-18
IL102813A (en) 1999-07-14
AP525A (en) 1996-09-06
PT100779B (pt) 1999-07-30
EP0641203A4 (en) 1994-06-09
MA22626A1 (fr) 1993-04-01
RO113643B1 (ro) 1998-09-30
SK13594A3 (en) 1994-08-10
AU2475692A (en) 1993-03-16
MX9204737A (es) 1994-02-28
FI940642A0 (fi) 1994-02-11
PT100779A (pt) 1993-09-30
NO940476D0 (no) 1994-02-11

Similar Documents

Publication Publication Date Title
NO305172B1 (no) (E)-3-[2-n-butyl-1-{ (4-karboksyfenyl)metyl}-1H-imidazol-5-yl]-2-(2-tienyl)metyl-2-propensyremetansulfonat, farmas°ytisk preparat pÕ basis av og anvendelse derav
NO924768D0 (no) Farmasoeytisk preparat og fremgangsmaate for dets fremstilling
NO308296B1 (no) Indolyl neuropeptid Y reseptorantagonister, farmasøytisk formulering omfattende samme og anvendelse av samme for fremstilling av legemiddel
DE69925262D1 (de) Pharmazeutika zur bildgebung der angiogenischen krankheiten
NO307335B1 (no) Substituerte N-(indol-2-karbonyl)-<beta>-alaninamider, anvendelse derav og farmasøytisk preparat
NO308533B1 (no) Heteroarylaminer, anvendelse derav og farmasøytisk preparat
NO307707B1 (no) Spiroazabicykliske forbindelser, farmasøytisk preparat inneholdende slike forbindelser og anvendelse derav
NO922506L (no) Farmasoeytiske preparat
NO922006L (no) Farmasoeytisk preparat
NO941719D0 (no) Farmasöytisk preparat med regulert frigjöringsvirkning
NO914623L (no) Doserings- og spraypumpe for overfoering av flytende, lav-viskose og pasta-formige substanser
NO306398B1 (no) Substituerte N-(indol-2-karbonyl) glycinamider, anvendelse derav, mellomprodukt og farmasöytisk preparat
NO20014963D0 (no) Cycloalkyl-substituerte benzimidazoler, samt fremstilling og anvendelse derav
EE200100391A (et) Peptidüül-heterotsüklilised ketoonid, nende kasutamine ja farmatseutiline kompositsioon
PT1194153E (pt) Formulacoes farmaceuticas liquidas com sabor mascarado
DE69223522D1 (de) Spielsalonsystem mit bezahlung am ende der spiele
NO973243D0 (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av gynekologiske sykdommer
NO975037L (no) Preparat omfattende amoxycillin og clavulansyre
FR2793688B1 (fr) Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
PT1228039E (pt) N-guanidinoalquilamidas sua preparacao sua utilizacao e preparacoes farmaceuticas contendo as mesmas
BR9707657A (pt) Benzotiofenos formulações contendo os mesmos e métodos
BR9708248A (pt) Benzotiofenos formulações contendo os mesmos e metódos
EE200100051A (et) Vastavast (-)-stereoisomeerist põhiliselt vaba (+)-nortsisapriidi või selle farmatseutiliselt vastuvõetava soola kasutamine ja farmatseutiline kompositsioon
NO990707D0 (no) Farmas°ytisk preparat inneholdende 4-oksobutansyrer
NO20001717D0 (no) Serotonin-inneholdende formulering for oral administrering og anvendelse av samme

Legal Events

Date Code Title Description
MK1K Patent expired